DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Felip E et al.
Phase II activity of the HSP90 Inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Ann Oncol 2012;
23 (Suppl. 09) Abstr. 4380
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.